Open access
Sep 2026
Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer
Abstract Background Pembrolizumab monotherapy is standard of care in first line treatment of patients with stage IV lung cancer and programmed death ligand 1 (PD-L1) expression ≥ 50%. Whether the higher levels of PD-L1 expression predict higher benefit from the treatment with pembrolizumab is still debatable. Patients...
V. Stojšić, B. Zarić, P. Simurdić et al.
· Radiology and Oncology · 0 citations